La EM, Bunniran S, Garbinsky D, Reynolds M, Schwab P, Poston S, Harrington L. Respiratory syncytial virus knowledge, attitudes, and perceptions among adults in the United States. Hum Vaccin Immunother. 2023 Dec 31;20(1):2303796. doi: 10.1080/21645515.2024.2303796
Curran D, Patterson BJ, Carrico J, Salem A, La EM, Lorenc Stephane, Hicks KA, Poston S, Carpenter CF. Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer. Hum Vaccin Immunother. 2023 Dec 31;19(1):2167907. doi: 10.1080/21645515.2023.2167907
Marriott BR, Walker MR, Howard J, Puspitasari A, Scott K, Albright K, Lewis CC. Taking a magnifying glass to measurement-based care consultation sessions: with what issues do mental health clinicians struggle? Adm Policy Ment Health. 2023 May;50(3):366-78. doi: 10.1007/s10488-022-01244-9
Herrera-Restrepo O, Ghaswalla P, Davis K, Sweeney C, Davenport E, Trofa A, Buck PM. Hepatitis A and Hepatitis B vaccination in adult patients at risk: a survey of US healthcare providers' attitudes and practices. Hum Vaccin Immunother. 2022 Nov 30;18(6):2123180. doi: 10.1080/21645515.2022.2123180
Herrera-Restrepo O, Davis K, Sweeney C, Davenport E, Ghaswalla P, Buck PO. Hepatitis A and B vaccination in adults at risk: a survey of US healthcare providers' attitudes and practices. Hum Vaccin Immunother. 2022 Nov 30;18(6):2123180. doi: 10.1080/21645515.2022.2123180
Poirrier JE, DeMartino JK, Nagar S, Carrico J, Hicks K, Meyers J, Stoddard J. Burden of opioid use for pain management among adult herpes zoster patients in the US and the potential impact of vaccination. Hum Vaccin Immunother. 2022 Nov;18(5):2040328. doi: 10.1080/21645515.2022.2040328
Carrasquilla G, Porras-Ramirez A, Martinez S, DeAntonio R, Devadiga R, Talarico C, Caceres DC, Castrejon MM, Juliao P. Trends in all-cause pneumonia and otitis media in children aged <2 years following pneumococcal conjugate vaccine introduction in Colombia. Hum Vaccin Immunother. 2021 Apr 3;17(4):1173-80. doi: 10.1080/21645515.2020.1805990
Talbird SE, La EM, Carrico J, Poston S, Poirrier JE, DeMartino JK, Hogea CS. Impact of population aging on the burden of vaccine-preventable diseases among older adults in the United States. Hum Vaccin Immunother. 2020 Aug 6;1-12. doi: 10.1080/21645515.2020.1780847
Graham J, Wolfson LJ, Kyle J, Perez Bolde-Villarreal C, Guarneros-DeRegil DB, Monsanto H, Pillsbury M, Talbird S, Daniels VJ. Budget impact analysis of multiple varicella vaccination strategies: a Mexico perspective. Hum Vaccin Immunother. 2019 Dec 18;16(4):886-94. doi: 10.1080/21645515.2019.1672491
La EM, Talbird SE, Kanadanian KV, Huang L, Fain J, Srivastava A. Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease. Hum Vaccin Immunother. 2019 Apr 3;15(4):978-86. doi: 10.1080/21645515.2018.1556074
Curran D, Patterson BJ, Van-Oorschot D, Buck PO, Carrico J, Hicks KA, Lee B, Yawn BP. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live. Hum Vaccin Immunother. 2019;15(4):765-71. doi: 10.1080/21645515.2018.1558689.
Luna-Casas G, Juliao P, Carreno-Manjarrez R, Castaneda-Prado A, Cervantes-Apolinar MY, Navarro-Rodriguez R, Sanchez-Gonzalez G, Cortes-Alcala R, DeAntonio R. Vaccine coverage and compliance in Mexico with the two-dose and three-dose rotavirus vaccines. Hum Vaccin Immunother. 2019;15(6):1251-9. doi: 10.1080/21645515.2018.1540827
Wasserman M, Palacios MG, Grajales AG, Berenice Baez-Revueltas F, Wilson M, McDade C, Farkouh R. Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico. Hum Vaccin Immunother. 2019;15(3):560-9. doi: 10.1080/21645515.2018.1516491
Hoffman V, Abu-Elyazeed R, Enger C, Esposito DB, Doherty MC, Quinlan SC, Skerry K, Holick CN, Basile P, Friedland LR, Praet N, Wery S, Willame C, Dore DD, Rosillon D. Safety study of live, oral human rotavirus vaccine: a cohort study in United States health insurance plans. Hum Vaccin Immunother. 2018 Jul 3;14(7):1782-90. doi: 10.1080/21645515.2018.1450123
La EM, Trantham L, Kurosky SK, Odom D, Aris E, Hogea C. An analysis of factors associated with influenza, pneumoccocal, Tdap, and herpes zoster vaccine uptake in the US adult population and corresponding inter-state variability. Hum Vaccin Immunother. 2018 Feb 1;14(2):430-41. doi: 10.1080/21645515.2017.1403697
Kurosky SK, Davis KL, Krishnarajah G. Effect of combination vaccines on completion and compliance of childhood vaccinations in the United States. Hum Vaccin Immunother. 2017 Nov;2(13):2494-502. doi: 10.1080/21645515.2017.1362515
Meyers JL, Madhwani S, Rausch D, Candrilli SD, Krishnarajah G, Yan S. Analysis of real-world health care costs among immunocompetent patients aged 50 years or older with herpes zoster in the United States. Hum Vaccin Immunother. 2017 Aug 3;13(8):1861-72.
Brogan AJ, Talbird SE, Davis AE, Thommes EW, Meier G. Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: a dynamic transmission modeling approach. Hum Vaccin Immunother. 2017 Mar 4;13(3):533-42. doi: 10.1080/21645515.2016.1242541
Willame C, Rosillon D, Zima J, Angelo MG, Stuurman AL, Vroling H, Boggon R, Bunge EM, Pladevall-Vila M, Baril L. Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom. Hum Vaccin Immunother. 2016 Nov;12(11):2862-71. doi: 10.1080/21645515.2016.1199308
Williams VS, Nelson LM, Fehnel SE, MacDougall J, Carson RT, Tourkodimitris S, Kurtz C, Baird MJ, Johnston JM. Psychometric validation of symptom severity measures in irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2014 Aug;40(3):298-308. doi: 10.1111/apt.12830
Rubin DT, Mody R, Davis KL, Wang CC. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. Aliment Pharmacol Ther. 2014 May;39(10):1143-55. doi: 10.1111/apt.12727
Karve SJ, Krishnarajah G, Korsnes JS, Cassidy A, Candrilli SD. Burden of acute gastroenteritis, norovirus and rotavirus in a managed care population. Hum Vaccin Immunother. 2014 Apr;10:1544-66. doi: 10.4161/hv.28704
Karve S, Misurski DA, Meier G, Davis KL. Employer-incurred health care costs and productivity losses associated with influenza. Hum Vaccin Immunother. 2013 Apr 1;9(4):841-57.
Huerta C, Rivero E, Montoro MA, García-Rodriguez LA. Risk factors for intestinal ischaemia among patients registered in a UK primary care database: a nested case-control study. Aliment Pharmacol Ther. 2011 Apr;33(8):969-78. doi: 10.1111/j.1365-2036
Earnshaw SR, Klok RM, Iyer S, McDade C. Methylnaltrexone bromide for the treatment of opioid-induced constipation in patients with advanced illness--a cost-effectiveness analysis. Aliment Pharmacol Ther. 2010 Apr 1;31(8):911-21.
Cook SF, Lanza L, Zhou X, Sweeney CT, Goss D, Hollis K, Mangel AW, Fehnel SE. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther. 2008 Jun 15;27(12):1224-32.
Davis KL, Candrilli SD, Edin HM. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia. 2008 Mar 1;49(3):446-54.
McAfee AT, Chilcott KE, Johannes CB, Hornbuckle K, Hauser WA, Walker AM. The incidence of first provoked and unprovoked seizure in pediatric patients with and without psychiatric diagnoses. Epilepsia. 2007 Jun 1;48(6):1075-82.
Tennis P, Andrews E, Hickman P, Miller D, Hollis KA, Cook S. The relationship between dosing of alosetron and discontinuation patterns reported by patients participating in a follow-up programme. Aliment Pharmacol Ther. 2007 Feb 1;25(3):317-22.
Miller DP, Bennett L, Hollis KA, Tennis P, Cook SF, Andrews E. A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme. Aliment Pharmacol Ther. 2006 Sep 1;24(5):869-78.
Mangel AW, Fehnel SE. Global endpoints in functional gastrointestinal disease. Aliment Pharmacol Ther. 2005 Dec 1;22(11-12):1162-3.
Andrews EB, Eaton SC, Hollis KA, Hopkins JS, Ameen VZ, Hamm LR, Mangel AW, Tennis P, Cook SF. Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment Pharmacol Ther. 2005 Nov 10;22:935-42.
Vakil N, Hahn B, McSorley DJ. Recurrent symptoms and gastro-oesophageal reflux disease in patient with duodenal ulcer treated for helicobacter pylori infection. Aliment Pharmacol Ther. 2000 Jan;14(1):45-51.
Camilleri M, Mayer EA, Drossman DA, Heath AT, Dukes GE, McSorley DJ, Kong S, Mangel AW, Northcutt AR. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999 Sep;13(9):1149-59.
Arana A. A North American Registry for epilepsy and pregnancy, a unique public/private partnership of health surveillance. Epilepsia. 1998 Jul;39(7):793-8.
Peterson WL, Ciociola AA, Sykes DL, McSorley DJ, Webb DD. Ranitidine bismuth citrate (tritec) plus clarithromycin is effective for healing duodenal ulcers, eradicating h.pylori, and reducing ulcer recurrence. Aliment Pharmacol Ther. 1996;10(3):251-61.
Dalla Bernardina B, Fontana E, Vigevano F, Fusco L, Torelli D, Galeone D, Buti D, Ciancheti C, Gnanasakthy A, Iudice A. Efficacy and tolerability of vigabatrin in children with refractory partial seizures: a single-blind dose-increasing study. Epilepsia. 1995 Jul;36(7):687-91.